

<b>Form PTO-1449</b> (Rev. 8-83) (modified)	<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>	<b>ATTY. DOCKET NO.</b> 12169US04	<b>SERIAL NO.</b> 09/385,114
		<b>APPLICANT(s):</b> Whitehouse	
		<b>FILING DATE</b> August 27, 1999	<b>GROUP ART UNIT:</b> 1653

**INFORMATION DISCLOSURE CITATION**  
 (Use several sheets if necessary)



**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JAR</i>	A21	4,378,347	03/29/83	Franco	424	108	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NO.	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
JAR	C54	Folkman, <i>Angiogenic Therapy of the Human Heart</i> , Circulation, <b>97</b> :628-629 (1998)
↓	C55	Kirschner, et al., <i>Basic fibroblast growth factor protects against ecitotoxicity and chemical hypoxia in both neonatal and adult rats</i> . Journal of Cerebral Blood Flow and Metabolish, <b>15</b> (4):619-623 (1995)
	C56	Sellke et al., <i>Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia</i> , Surgery <b>120</b> (2):82-188 (1996)
	C57	PCT International Search Report Application No. PCT/US99/22936, filed October 13, 1999

<b>EXAMINER</b> <i>Hope Robinson</i>	<b>DATE CONSIDERED:</b> 11/30/00
---	-------------------------------------

\*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.